Vigonvita Sciences

Vigonvita Sciences (Shanghai) Co., Ltd. is a China-based biotechnology company focused on developing AAV gene therapies for rare neurological and genetic diseases. The company is leveraging established AAV manufacturing capabilities and expertise in neurodevelopmental disorders to build a pipeline of transformative therapies for conditions including [CDKL5 deficiency disorder](/diseases/cdkl5-deficiency-disorder) and related disorders[vigonvita2024].

Overview

Vigonvita is positioned at the intersection of China's rapidly growing biopharmaceutical sector and the global rare disease gene therapy landscape. The company has developed integrated capabilities in:

• AAV vector engineering and design
• GMP manufacturing for gene therapy products
• Regulatory strategy for rare neurological diseases
• Clinical development for pediatric populations

The company's primary focus is on monogenic neurological diseases where AAV-mediated gene delivery can provide meaningful clinical benefit with a single treatment administration[vigonvita2023].

Pipeline

VGN-XXX (CDKL5 Deficiency Disorder)

CDKL5 deficiency disorder is a severe neurodevelopmental condition caused by loss-of-function mutations in the [CDKL5](/genes/cdkl5) gene, characterized by early-onset seizures, developmental delay, and motor dysfunction. Vigonvita is developing an AAV gene therapy to deliver a functional copy of [CDKL5](/genes/cdkl5) to affected neurons[cdkl5pipeline].

...

Vigonvita Sciences (Shanghai) Co., Ltd. is a China-based biotechnology company focused on developing AAV gene therapies for rare neurological and genetic diseases. The company is leveraging established AAV manufacturing capabilities and expertise in neurodevelopmental disorders to build a pipeline of transformative therapies for conditions including [CDKL5 deficiency disorder](/diseases/cdkl5-deficiency-disorder) and related disorders[vigonvita2024].

Overview

Vigonvita is positioned at the intersection of China's rapidly growing biopharmaceutical sector and the global rare disease gene therapy landscape. The company has developed integrated capabilities in:

• AAV vector engineering and design
• GMP manufacturing for gene therapy products
• Regulatory strategy for rare neurological diseases
• Clinical development for pediatric populations

The company's primary focus is on monogenic neurological diseases where AAV-mediated gene delivery can provide meaningful clinical benefit with a single treatment administration[vigonvita2023].

Pipeline

VGN-XXX (CDKL5 Deficiency Disorder)

CDKL5 deficiency disorder is a severe neurodevelopmental condition caused by loss-of-function mutations in the [CDKL5](/genes/cdkl5) gene, characterized by early-onset seizures, developmental delay, and motor dysfunction. Vigonvita is developing an AAV gene therapy to deliver a functional copy of [CDKL5](/genes/cdkl5) to affected neurons[cdkl5pipeline].

Program Status (March 2026):

• IND-enabling studies underway
• IND filing anticipated 2026
• Preclinical data supporting CNS delivery and expression
• Manufacturing scale-up for clinical supply

Mechanism:

• AAV vector (serotype selection optimized for CNS tropism)
• Delivers full-length human CDKL5 cDNA
• Intrathecal or intracisternal administration
• Single-dose treatment

Development Considerations:

• CDKL5 gene size (~4.8kb) fits within standard AAV cargo capacity
• Cell-type targeting to excitatory neurons and specific brain regions
• Juvenile toxicology studies in relevant models
• Formulation optimized for pediatric administration

Additional Pipeline Programs

Vigonvita has indicated additional programs in development:

| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| VGN-XXX (preclinical) | Undisclosed | Neurological disorder | Discovery |
| VGN-XXX (preclinical) | Undisclosed | Genetic epilepsy | Discovery |

Manufacturing Capabilities

A key differentiator for Vigonvita is its established AAV manufacturing infrastructure:

• GMP production: Established facilities in Shanghai capable of producing clinical-grade AAV
• Scalable platform: Suspension cell culture systems for large-scale production
• Quality systems: GMP compliance with international standards (FDA, EMA compatibility)
• Vertical integration: In-house manufacturing enables cost control and supply security

This manufacturing capability allows Vigonvita to progress programs through clinical development without requiring third-party manufacturing agreements, which have been a bottleneck for many gene therapy companies[vigonvita2025].

Competitive Position

Vigonvita competes in the CDKL5 gene therapy landscape with:

| Competitor | Approach | Stage |
|-----------|----------|-------|
| [Ultragenyx](/companies/ultragenyx) | Enzyme replacement (sebelipase alfa analog) | Preclinical |
| Academic groups | Various AAV approaches | Preclinical |
| [Vigonvita Sciences](/companies/vigonvita-sciences) | AAV gene therapy | IND-enabling |

Advantages:

• Established manufacturing capacity
• China-based operations with access to large patient population
• Competitive cost structure
• Focus on underserved rare neurological diseases

Risks:

• Earlier stage than more established competitors
• Regulatory pathway across multiple jurisdictions
• Limited public data on clinical programs
• International regulatory acceptance of China-based data

Corporate Structure

• Headquarters: Shanghai, China
• Type: Private company
• Focus: Rare neurological diseases, gene therapy
• Manufacturing: Integrated GMP facilities
• Stage: IND-enabling for lead program

Hub Page Cross-Links

• [AAV Gene Therapy for Neurodevelopmental Epilepsy — Hub](/therapeutics/aav-gene-therapy-neurodevelopmental-epilepsy)](/therapeutics)
• [CDKL5 Deficiency Disorder Disease Page](/diseases/cdkl5-deficiency-disorder)](/entities/cdkl5)
• [CDKL5 Gene Page](/genes/cdkl5)](/genes)
• [Vigonvita CDKL5 Deficiency — Preclinical Program](/clinical-trials/vigonvita-cdkl5-deficiency-preclinical)